Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Biogen Pharmachem Industries Ltd has submitted a nil disclosure to BSE under SEBI's Regulation 32(1). The company confirms that as of March 31, 2026, there are no unutilized proceeds remaining from any public issue, rights issue, preferential issue, or qualified institutional placement (QIP) undertaken in the past. Since all funds have been fully deployed, the company is not required to submit the detailed Annexure-A statement that would typically accompany such disclosures when deviations exist.
This is a routine compliance filing indicating healthy fund utilization with no deviations from stated objects. It carries no direct impact on the stock price but assures shareholders that issue proceeds were deployed as intended.